GlaxoSmithKline

Pharmaceuticals

GSK

$ 42 (0.09)%

Share price

$ 86 bn

Market Cap

$ 184 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.12x the weighted average for S&P 500

FY2022

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Stronger than the -9.3% weighted average for S&P 500

FY2023

GlaxoSmithKline aims to achieve net zero for Scope 1 + 2 by 2030

1.5°C

Secondary Climate Goal

Proj. YOY change in GHG emissions (all Scopes)

Stronger than the -1.4% weighted average for S&P 500

FY2022

GlaxoSmithKline aims to reduce all Scopes by 80% by 2030 from a base year 2020

1.5°C

GHG emissions and Carbon intensity

GlaxoSmithKline reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2022 at 714 Kt (-126 /-15% y-o-y). Also positively, carbon intensity decreased to 18 t (-2 /-10.1% y-o-y).

GlaxoSmithKline's Scope 3 emissions tumbled to 8,624 Kt (-4,832 /-35.9% y-o-y). This is a higher rate of decline than over the period since 4Q'15 (-10.5% CAGR).

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -89 Kt per annum over the period of FY2023 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Also, the company commits to reducing all Scopes by 80% by 2030 from a base year 2020, which translates into the estimated reduction of -733 Kt per annum over the period of FY2022 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2022Q4	714	626	88
2021Q4	840	681	159	8,624	46,809	18
2020Q4	880	764	227	13,456	44,221	20
2019Q4	1,060	798	348	14,620	43,207	25
2018Q4	1,346	822	524	16,335	40,999	33
2017Q4	1,482	865	590	18,153	39,136	38
2016Q4	1,507	888	618	17,896	37,776	40
2015Q4	1,573	888	685	18,689	36,347	43